Cantor Fitzgerald Reiterates Overweight on Taysha Gene Therapies, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $7 price target.
April 19, 2024 | 2:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald maintains an Overweight rating and a $7 price target on Taysha Gene Therapies.
The reiteration of an Overweight rating and maintenance of a $7 price target by a reputable analyst like Kristen Kluska from Cantor Fitzgerald could signal a strong vote of confidence in Taysha Gene Therapies. This endorsement may positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100